Did Light and Wonder delist?
Yes, Eli Lilly and Company reached a definitive agreement on March 31, 2026, to acquire Centessa Pharmaceuticals in a transaction valued at up to $7.8 billion. This acquisition provides Lilly with access to Centessa's promising orexin receptor 2 (OX2R) agonist pipeline, notably the drug cleminorexton. This pipeline is being developed to treat sleep-wake disorders such as narcolepsy and idiopathic hypersomnia, which are characterized by excessive daytime sleepiness. The deal includes an upfront cash payment of $38 per share, valuing the company at approximately $6.3 billion, plus contingent value rights of up to $9 per share tied to specific U.S. regulatory milestones. This move highlights Lilly’s strategic expansion into neuroscience and sleep medicine by focusing on a mechanism that aims to correct the underlying signaling deficits rather than just managing symptoms.
Related FAQs
Yes, Light & Wonder, Inc. officially delisted its common stock from the Nasdaq Stock Market in November 2025.
Meezan Bank Limited supports a comprehensive workforce numbering approximately nineteen thousand seven hundred twenty-two employees operating within the Islamic banking and financial services sector.